Gilead Reports real-world evidence Data for Osimertinib in Breast cancer

Gilead today announced real-world evidence results for osimertinib in patients with breast cancer. The study demonstrated that osimertinib achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of breast cancer and support the continued development of osimertinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.